Compare Colgate-Palmolive Company (CL) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Colgate-Palmolive Company vs Moderna, Inc. — how do they compare? Colgate-Palmolive Company trades at $92.31 (market cap $73.59B), while Moderna, Inc. trades at $60.81 (market cap $24.18B). The key difference: Colgate-Palmolive Company is far larger — about 3× Moderna, Inc.'s market cap, and Colgate-Palmolive Company pays a 2.3% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| CL | MRNA | |
|---|---|---|
Market Cap | $73.59B | $24.18B |
Sector | Consumer Staples | Health |
52-Week High | $99.14 | $81.80 |
52-Week Low | $74.98 | $22.36 |
Enterprise Value | $80.07B | $20.33B |
Dividend Yield | 2.3% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Colgate-Palmolive Company
Since its founding in 1806, Colgate-Palmolive has grown to become a leading global consumer product company. In addition to its namesake oral care line, the firm manufactures shampoos, shower gels, deodorants, and home care products that are sold in over 200 countries (international sales account for about 70% of its consolidated total, including approximately 45% from emerging regions). It also owns specialty pet food maker Hill's, which sells its products through veterinarians and specialty pet retailers.
Read more on CL →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
